Cargando…

Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022

We used data of 32,542 prospective cohort study participants who previously received primary and one or two monovalent booster COVID-19 vaccinations. Between 26 September and 19 December 2022, relative effectiveness of bivalent original/Omicron BA.1 vaccination against self-reported Omicron SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huiberts, Anne J, de Gier, Brechje, Hoeve, Christina E, de Melker, Hester E, Hahné, Susan JM, den Hartog, Gerco, van de Wijgert, Janneke HHM, van den Hof, Susan, Knol, Mirjam J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2023
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936593/ https://www.ncbi.nlm.nih.gov/pubmed/36795500 http://dx.doi.org/10.2807/1560-7917.ES.2023.28.7.2300087

Ejemplares similares

Vaccine effectiveness of primary and booster COVID-19 vaccinations against SARS-CoV-2 infection in the Netherlands from July 12, 2021 to June 6, 2022: A prospective cohort study
por: Huiberts, Anne J., et al.
Publicado: (2023)

Effects of COVID-19 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with serology
por: de Gier, Brechje, et al.
Publicado: (2023)

Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Delta and Omicron Infection and Infectiousness Within Households in the Netherlands Between July 2021 and August 2022
por: Hoeve, Christina E, et al.
Publicado: (2023)

Transmissibility of SARS-CoV-2 among fully vaccinated individuals
por: Knol, Mirjam J, et al.
Publicado: (2022)

Higher risk of SARS-CoV-2 Omicron BA.4/5 infection than of BA.2 infection after previous BA.1 infection, the Netherlands, 2 May to 24 July 2022
por: Andeweg, Stijn P, et al.
Publicado: (2023)

COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021
por: van Ewijk, Catharina E, et al.
Publicado: (2022)

Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021–January 2022
por: de Gier, Brechje, et al.
Publicado: (2023)

Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
por: Andeweg, Stijn P., et al.
Publicado: (2022)

Number of COVID-19 hospitalisations averted by vaccination: Estimates for the Netherlands, January 6, 2021 through August 30, 2022
por: van Iersel, Senna C.J.L., et al.
Publicado: (2023)

Out-of-season increase of puerperal fever with group A Streptococcus infection: a case–control study, Netherlands, July to August 2018
por: van den Boogaard, Jossy, et al.
Publicado: (2020)

Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis
por: Nic Lochlainn, Laura M, et al.
Publicado: (2019)

Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis
por: Nic Lochlainn, Laura M, et al.
Publicado: (2019)

Occupation- and age-associated risk of SARS-CoV-2 test positivity, the Netherlands, June to October 2020
por: de Gier, Brechje, et al.
Publicado: (2020)

The dynamics of scarlet fever in The Netherlands, 1906–1920: a historical analysis
por: McDonald, Scott A., et al.
Publicado: (2022)

Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021
por: de Gier, Brechje, et al.
Publicado: (2021)

Assessment of hybrid population immunity to SARS-CoV-2 following breakthrough infections of distinct SARS-CoV-2 variants by the detection of antibodies to nucleoprotein
por: den Hartog, Gerco, et al.
Publicado: (2023)

Age‐specific severity of severe acute respiratory syndrome coronavirus 2 in February 2020 to June 2021 in the Netherlands
por: de Boer, Pieter T., et al.
Publicado: (2023)

COVID-19 Bivalent Booster Vaccination Coverage and Intent to Receive Booster Vaccination Among Adolescents and Adults — United States, November–December 2022
por: Lu, Peng-jun, et al.
Publicado: (2023)

The estimated disease burden of acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years
por: McDonald, Scott A., et al.
Publicado: (2022)

COVID-19 outbreak in an elderly care home: Very low vaccine effectiveness and late impact of booster vaccination campaign
por: van Ewijk, Catharina E., et al.
Publicado: (2022)

Durability of Bivalent Boosters against Omicron Subvariants
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Mumps Vaccine Effectiveness Against Orchitis
por: Hahné, Susan, et al.
Publicado: (2012)

Epidemic of Mumps among Vaccinated Persons, the Netherlands, 2009–2012
por: Sane, Jussi, et al.
Publicado: (2014)

Disease burden of neonatal invasive Group B Streptococcus infection in the Netherlands
por: de Gier, Brechje, et al.
Publicado: (2019)

Mumps transmission in social networks: a cohort study
por: Hahné, Susan, et al.
Publicado: (2017)

Early effect of bivalent human papillomavirus vaccination on cytology outcomes in cervical samples among young women in the Netherlands
por: Schurink‐van ’t Klooster, Tessa M., et al.
Publicado: (2023)

Reasons for Receiving or Not Receiving Bivalent COVID-19 Booster Vaccinations Among Adults — United States, November 1–December 10, 2022
por: Sinclair, Alyssa H., et al.
Publicado: (2023)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Effectiveness of Bivalent Boosters against Severe Omicron Infection
por: Lin, Dan-Yu, et al.
Publicado: (2023)

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol
por: Tan, Ngoc H., et al.
Publicado: (2022)

Impact of physical distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Netherlands, 2016–17, April 2020 and June 2020
por: Backer, Jantien A, et al.
Publicado: (2021)

Vaccine effectiveness against SARS-CoV-2 transmission to household contacts during dominance of Delta variant (B.1.617.2), the Netherlands, August to September 2021
por: de Gier, Brechje, et al.
Publicado: (2021)

The use of tetanus post-exposure prophylaxis guidelines by general practitioners and emergency departments in the Netherlands: a cross-sectional questionnaire study
por: Donken, Robine, et al.
Publicado: (2014)

Disease burden of varicella versus other vaccine-preventable diseases before introduction of vaccination into the national immunisation programme in the Netherlands
por: van Lier, Alies, et al.
Publicado: (2019)

Estimating the asymptomatic proportion of SARS-CoV-2 infection in the general population: Analysis of nationwide serosurvey data in the Netherlands
por: McDonald, Scott A., et al.
Publicado: (2021)

EE329 The Value-Based Price for a Bivalent COVID-19 Booster Vaccine in the United Kingdom
por: Kohli, M., et al.
Publicado: (2023)

Determinants of COVID-19 Vaccine Uptake in The Netherlands: A Nationwide Registry-Based Study
por: Pijpers, Joyce, et al.
Publicado: (2023)

Participation in and attitude towards the national immunization program in the Netherlands: data from population-based questionnaires
por: Mollema, Liesbeth, et al.
Publicado: (2012)

Nitrofurantoin failure in males with an uncomplicated urinary tract infection: a primary care observational cohort study
por: Platteel, Tamara N, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0bbekdr5hs2skbq862j53r213l